Want to see PRGO full AI Analyst Report?
PRGO Stock Chart & Stats
$14.48
$0.27(2.68%)
At close: 4:00 PM EDT
$14.48
$0.27(2.68%)
Day’s Range― - ―
52-Week Range$9.23 - $23.68
Previous CloseN/A
Volume1.22M
Average Volume (3M)2.89M
Market Cap
$2.01B
Enterprise Value$4.45K
Total Cash (Recent Filing)$399.70M
Total Debt (Recent Filing)$3.29B
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 11, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield8.13%
Share Statistics
EPS (TTM)-12.51
Shares Outstanding138,769,240
10 Day Avg. Volume2,692,295
30 Day Avg. Volume2,894,990
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.45
P/FCF Ratio13.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.00Price Target Upside17.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.2
Revenue Forecast (FY)$4.05B
Bulls Say, Bears Say
Bulls Say
Market Share And Service ImprovementsOutgrowing declining categories and improving service levels strengthen retailer relationships and distribution reliability. These operational gains can support durable share retention and better execution across Perrigo’s private-label and branded portfolio.
Innovation And Cost-Savings PipelineA larger, platform-based innovation pipeline can support new product launches and distribution growth, while the multiyear enhancement program offers a path to offset cost pressure. Together, they provide structural levers for improving productivity and competitiveness.
Positive Cash Generation And Debt ReductionPositive operating and free cash flow provide internal funding for investment, dividends and deleveraging despite accounting losses. Applying divestiture proceeds to debt should reduce interest burden and improve financial flexibility if cash generation remains sustainable.
Bears Say
Persistent Revenue ContractionSustained sales declines indicate weak category demand, retailer destocking and portfolio pressure rather than simple volatility. Lower volumes can weaken manufacturing absorption, reduce bargaining power and make it harder to convert innovation and distribution initiatives into growth.
Margin And Earnings DeteriorationMargin compression combined with large losses signals impaired earnings quality and elevated execution risk. Planned under-absorption is expected to reduce 2026 all-in EPS by about $0.60, potentially limiting reinvestment capacity until volumes and productivity recover.
Elevated LeverageAlthough debt has been reduced, leverage remains high relative to equity and profitability is currently negative. This constrains financial flexibility, leaves cash flow more exposed to interest obligations and increases the importance of successful deleveraging and operational recovery.
Perrigo Company News
PRGO FAQ
What was Perrigo Company plc’s price range in the past 12 months?
Perrigo Company plc lowest stock price was $9.22 and its highest was $23.68 in the past 12 months.
What is Perrigo Company plc’s market cap?
Perrigo Company plc’s market cap is $2.01B.
When is Perrigo Company plc’s upcoming earnings report date?
Perrigo Company plc’s upcoming earnings report date is Nov 11, 2026 which is in 67 days.
How were Perrigo Company plc’s earnings last quarter?
Perrigo Company plc released its earnings results on Aug 05, 2026. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.388 by $0.112.
Is Perrigo Company plc overvalued?
According to Wall Street analysts Perrigo Company plc’s price is currently Undervalued.
Does Perrigo Company plc pay dividends?
Perrigo Company plc pays a Quarterly dividend of $0.29 which represents an annual dividend yield of 8.13%. See more information on Perrigo Company plc dividends here
What is Perrigo Company plc’s EPS estimate?
Perrigo Company plc’s EPS estimate is 0.52.
How many shares outstanding does Perrigo Company plc have?
Perrigo Company plc has 138,769,240 shares outstanding.
What happened to Perrigo Company plc’s price movement after its last earnings report?
Perrigo Company plc reported an EPS of $0.5 in its last earnings report, beating expectations of $0.388. Following the earnings report the stock price went up 23.102%.
Which hedge fund is a major shareholder of Perrigo Company plc?
Currently, no hedge funds are holding shares in PRGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perrigo Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (17.40% Upside)
$17.00 (17.40% Upside)
Blogger Sentiment
Bullish
PRGO Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.06%
12-Months-Change
Fundamentals
Return on Equity
8.13%
Trailing 12-Months
Asset Growth
-24.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
PRGO Company Deck
PRGO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational progress and strategic actions against ongoing top-line and margin pressures. Positive indicators include market share gains, substantial service-level improvements, a recovering Infant Formula business (+23% sales, +$60M operating income), acceleration of a scalable innovation pipeline, targeted cost-savings ($80–$100M program) and the use of $359M divestiture proceeds to reduce debt. Offsetting these positives were a 3%+ decline in net sales, 250 basis points of gross margin compression, notable retailer destocking (≈1.8% headwind), specialty segment weakness and an expected ~$0.60 EPS headwind in 2026 from under-absorption. Management maintained full-year guidance and emphasized that results are weighted to a stronger second half, signaling cautious optimism but acknowledging remaining execution and demand risks.View all PRGO earnings summariesPRGO Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$17.00
▲(17.40% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Viatris
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Indivior
―
Amneal Pharmaceuticals
―
Ownership Overview
0.38% Insiders
29.54% Mutual Funds
25.09% Other Institutional Investors
2.74% Public Companies and
Individual Investors









